key: cord-0905089-97ddidut
authors: Liu, Anne Y.
title: How important is the second dose of the COVID-19 mRNA vaccine?
date: 2021-06-07
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2021.02.061
sha: d1dacf14ca407c11eefaebfc3a8f66a3021d4722
doc_id: 905089
cord_uid: 97ddidut

nan

How important is the second dose of the COVID-19 mRNA vaccine?

To the Editor:

The current data and lack thereof for allergy guidance on coronavirus disease 2019 (COVID-19) mRNA vaccines was outlined beautifully by Banerji et al 1 and Greenhawt et al. 2 As allergists create algorithms and testing protocols to evaluate patients who have had possible allergic reactions to the first dose of the Pfizer/ BioNTech or Moderna vaccine, it also falls to allergists to counsel patients on the undefined benefit of the second dose.

Booster doses are intended to promote B-cell affinity maturation, increase neutralizing antibodies, and expand the memory T-cell pool. In practice, both COVID-19 mRNA vaccines confer excellent short-term protection starting 2 weeks after the first dose, before second-dose administration. Between days 15 and 21 after the first dose, symptomatic infections were reduced by almost 90% among Pfizer trial participants. 3 Among Moderna trial participants who received a single dose only, vaccine efficacy was 92% starting at day 14, with a median follow-up of 28 days. 4 Efficacy might suffer against variants such as B.1.351, and whether this difference would be affected by delaying a second dose is unknown.

In the short-term, the infection-related risk of delaying a second dose of mRNA vaccine by several weeks may be low. For those who experience a possible first-dose reaction, such a delay may allow patients time to gather information to guide a seconddose decision. Studies are ongoing on degree and duration of protection with a single dose, safety and efficacy of mixing vaccines (eg, adenovirus vaccine after mRNA vaccine), and impact of vaccine intervals on protection against or development of new variants. As allergists pursue various evaluation algorithms, we will find out more about the predictive value of skin testing, likelihood of second reactions, and efficacy of vaccines given by graded challenge.

Adenovirus vector vaccines may change allergists' algorithms. Johnson & Johnson has obtained emergency use authorization for its vaccine as a single dose, and AstraZeneca's vaccine data are encouraging for single-dose efficacy for at least 3 months. Combined data from AstraZeneca trials showed vaccine efficacy of 76% after a single dose, with stable antibody titers to day 90, compared with 67% overall efficacy after 2 doses, with noted demographic differences between subgroups. Among those who received 2 doses, prolonging the interval between doses to 3 months was associated with greater vaccine efficacy, at 82% and 55%, with dose intervals of 121 weeks and less than 6 weeks, respectively. 5 Motivated patients seeking clearance for a second mRNA vaccine dose tell us they want this ''life-saving'' protection. Yet we do not know whether the second dose confers substantial additional protection against hospitalization and death.

For the general population, both mRNA vaccine doses should be given as studied, supply permitting. For patients whose firstdose reactions have raised concerns about second-dose safety, the limited data on short-term single-dose efficacy should be weighed along with exposure risk and reaction severity.

mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach

The COVID-19 pandemic in 2021: avoiding overdiagnosis of anaphylaxis risk while safely vaccinating the world

Optimising the COVID-19 vaccination programme for maximum short-term impact: short statement from the Joint Committee on Vaccination and Immunisation (JCVI)

FDA briefing document: Moderna COVID-19 Vaccine

Single dose administration, and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine

COVID-19) vaccination. 2,3 Liu 1 raises several important points that highlight uncertainties surrounding the COVID-19 vaccination effort, suggesting that for some patients who experience a severe allergic reaction to a first mRNA vaccine dose, a second vaccine dose may be deferred or delayed in light of limited evidence demonstrating good short-term efficacy of a single dose. 1,4-6 Our understanding continues to rapidly evolve on this topic. For example, a recent study from the Sheba Medical Centre reported an 85% (95% CI, 71%-92%) reduction in symptomatic COVID-19 cases 15 to 28 days after the first dose of the Pfizer-BioNTech vaccine. 5 This reduction in symptomatic COVID-19 infection is improved from an original estimate for first-dose vaccine efficacy of 52.4% reported by Polack et al, 7 and may differ as a result of timing of the measurement. When considering the ratio of confirmed cases of COVID-19 illness in active versus placebo groups from Polack et al, Pfizer-BioNTech vaccine efficacy has been estimated at 92.6% beginning 14 days after dose 1 to before dose 2. 6 Indeed, this rate is similar to the first-dose efficacy rate of 92.1% reported for the Moderna vaccine. 6,8 Still, uncertainty remains regarding single-dose mRNA vaccine protection, as a recent population-based Israeli study including 596